Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Therapeutic advances in medical oncology

Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK.
PMID: 25755678
Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117.

OBJECTIVES: ALK-EML4 translocation is an established driver aberration in non-small cell lung cancer (NSCLC), with reported predilection for cases with signet ring histology. We assessed the presence of anaplastic lymphoma kinase (ALK) gene rearrangements in signet ring cancers arising...

Cite
Alese OB, El-Rayes BF, Sica G, et al. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015;7(2):56-62doi: 10.1177/1758834014567117.
Alese, O. B., El-Rayes, B. F., Sica, G., Zhang, G., Alexis, D., La Rosa, F. G., Varella-Garcia, M., Chen, Z., Rossi, M. R., Adsay, N. V., Khuri, F. R., & Owonikoko, T. K. (2015). Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Therapeutic advances in medical oncology, 7(2), 56-62. https://doi.org/10.1177/1758834014567117
Alese, Olatunji B, et al. "Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract." Therapeutic advances in medical oncology vol. 7,2 (2015): 56-62. doi: https://doi.org/10.1177/1758834014567117
Alese OB, El-Rayes BF, Sica G, Zhang G, Alexis D, La Rosa FG, Varella-Garcia M, Chen Z, Rossi MR, Adsay NV, Khuri FR, Owonikoko TK. Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. Ther Adv Med Oncol. 2015 Mar;7(2):56-62. doi: 10.1177/1758834014567117. PMID: 25755678; PMCID: PMC4346214.
Copy Download .nbib Format: NLM
Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques.

Genetics and molecular biology

Bellini MF, Silva AE, Varella-Garcia M.
PMID: 21637470
Genet Mol Biol. 2010 Apr;33(2):205-13. doi: 10.1590/S1415-47572010005000028. Epub 2010 Jun 01.

This review summarizes the chromosomal changes detected by molecular cytogenetic approaches in esophageal squamous cell carcinoma (ESCC), the ninth most common malignancy in the world. Whole genome analyses of ESCC cell lines and tumors indicated that the most frequent...

Cite
Bellini MF, Silva AE, Varella-Garcia M. Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genet Mol Biol. 2010;33(2):205-13doi: 10.1590/S1415-47572010005000028.
Bellini, M. F., Silva, A. E., & Varella-Garcia, M. (2010). Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genetics and molecular biology, 33(2), 205-13. https://doi.org/10.1590/S1415-47572010005000028
Bellini, Marilanda Ferreira, et al. "Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques." Genetics and molecular biology vol. 33,2 (2010): 205-13. doi: https://doi.org/10.1590/S1415-47572010005000028
Bellini MF, Silva AE, Varella-Garcia M. Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques. Genet Mol Biol. 2010 Apr;33(2):205-13. doi: 10.1590/S1415-47572010005000028. Epub 2010 Jun 01. PMID: 21637470; PMCID: PMC3036856.
Copy Download .nbib Format: NLM
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Oncotarget

Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF.
PMID: 28881577
Oncotarget. 2016 Jun 10;8(31):50489-50499. doi: 10.18632/oncotarget.9929. eCollection 2017 Aug 01.

Recent literature suggests that most widely used ovarian cancer (OVCA) cell models do not recapitulate the molecular features of clinical tumors. To address this limitation, we generated 18 cell lines and 3 corresponding patient-derived xenografts predominantly from high-grade serous...

Cite
Thu KL, Papari-Zareei M, Stastny V, et al. A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget. 2016;8(31):50489-50499doi: 10.18632/oncotarget.9929.
Thu, K. L., Papari-Zareei, M., Stastny, V., Song, K., Peyton, M., Martinez, V. D., Zhang, Y. A., Castro, I. B., Varella-Garcia, M., Liang, H., Xing, C., Kittler, R., Milchgrub, S., Castrillon, D. H., Davidson, H. L., Reynolds, C. P., Lam, W. L., Lea, J., & Gazdar, A. F. (2017). A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget, 8(31), 50489-50499. https://doi.org/10.18632/oncotarget.9929
Thu, Kelsie L, et al. "A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas." Oncotarget vol. 8,31 (2017): 50489-50499. doi: https://doi.org/10.18632/oncotarget.9929
Thu KL, Papari-Zareei M, Stastny V, Song K, Peyton M, Martinez VD, Zhang YA, Castro IB, Varella-Garcia M, Liang H, Xing C, Kittler R, Milchgrub S, Castrillon DH, Davidson HL, Reynolds CP, Lam WL, Lea J, Gazdar AF. A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget. 2016 Jun 10;8(31):50489-50499. doi: 10.18632/oncotarget.9929. eCollection 2017 Aug 01. PMID: 28881577; PMCID: PMC5584155.
Copy Download .nbib Format: NLM
Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs.

Polymers

Varela-Garcia A, Gomez-Amoza JL, Concheiro A, Alvarez-Lorenzo C.
PMID: 32899893
Polymers (Basel). 2020 Sep 04;12(9). doi: 10.3390/polym12092026.

A variety of ocular diseases are caused by viruses, and most treatments rely on the use of systemic formulations and eye drops. The efficient ocular barriers that oppose antiviral drug penetration have prompted the development of improved topical delivery...

Cite
Varela-Garcia A, Gomez-Amoza JL, Concheiro A, et al. Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs. Polymers (Basel). 2020;12(9)doi: 10.3390/polym12092026.
Varela-Garcia, A., Gomez-Amoza, J. L., Concheiro, A., & Alvarez-Lorenzo, C. (2020). Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs. Polymers, 12(9), . https://doi.org/10.3390/polym12092026
Varela-Garcia, Angela, et al. "Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs." Polymers vol. 12,9 (2020). doi: https://doi.org/10.3390/polym12092026
Varela-Garcia A, Gomez-Amoza JL, Concheiro A, Alvarez-Lorenzo C. Imprinted Contact Lenses for Ocular Administration of Antiviral Drugs. Polymers (Basel). 2020 Sep 04;12(9). doi: 10.3390/polym12092026. PMID: 32899893; PMCID: PMC7565425.
Copy Download .nbib Format: NLM
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.

Diagnostic pathology

Varella-Garcia M.
PMID: 16911776
Diagn Pathol. 2006 Aug 15;1:19. doi: 10.1186/1746-1596-1-19.

DNA fluorescence in situ hybridization (FISH) technology is used to study chromosomal and genomic changes in fixed cell suspensions and tissue block preparations. The technique is based on specific hybridization of small labeled DNA fragments, the probes, to complementary...

Cite
Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006;1:19doi: 10.1186/1746-1596-1-19.
Varella-Garcia, M. (2006). Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagnostic pathology, 119. https://doi.org/10.1186/1746-1596-1-19
Varella-Garcia, Marileila. "Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay." Diagnostic pathology vol. 1 (2006): 19. doi: https://doi.org/10.1186/1746-1596-1-19
Varella-Garcia M. Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol. 2006 Aug 15;1:19. doi: 10.1186/1746-1596-1-19. PMID: 16911776; PMCID: PMC1560164.
Copy Download .nbib Format: NLM
Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene.

Redox report : communications in free radical research

Wright RM, Weigel LK, Varella-Garcia M, Vaitaitis G, Repine JE.
PMID: 27406959
Redox Rep. 1997 Jun;3(3):135-44. doi: 10.1080/13510002.1997.11747101.

Aldehyde oxidase (AOX) is a member of the xanthine oxidase (XO) family of molybdenum hydroxylase, iron-sulfur flavoproteins and is involved in the metabolism of a wide range of native and xenobiotic compounds. The potentially toxic reduced oxygen intermediates (ROI),...

Cite
Wright RM, Weigel LK, Varella-Garcia M, et al. Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene. Redox Rep. 1997;3(3):135-44doi: 10.1080/13510002.1997.11747101.
Wright, R. M., Weigel, L. K., Varella-Garcia, M., Vaitaitis, G., & Repine, J. E. (1997). Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene. Redox report : communications in free radical research, 3(3), 135-44. https://doi.org/10.1080/13510002.1997.11747101
Wright, R M, et al. "Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene." Redox report : communications in free radical research vol. 3,3 (1997): 135-44. doi: https://doi.org/10.1080/13510002.1997.11747101
Wright RM, Weigel LK, Varella-Garcia M, Vaitaitis G, Repine JE. Molecular cloning, refined chromosomal mapping and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene. Redox Rep. 1997 Jun;3(3):135-44. doi: 10.1080/13510002.1997.11747101. PMID: 27406959.
Copy Download .nbib Format: NLM
Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience.

Archives of pathology & laboratory medicine

Aisner DL, Rumery MD, Merrick DT, Kondo KL, Nijmeh H, Linderman DJ, Doebele RC, Thomas N, Chesnut PC, Varella-Garcia M, Franklin WA, Camidge DR.
PMID: 27610643
Arch Pathol Lab Med. 2016 Nov;140(11):1206-1220. doi: 10.5858/arpa.2016-0156-RA. Epub 2016 Sep 09.

Context .- In an era in which testing of patient tumor material for molecular and other ancillary studies is of increasing clinical importance for selection of therapy, the ability to test on small samplings becomes critical. Often, small samplings...

Cite
Aisner DL, Rumery MD, Merrick DT, et al. Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med. 2016;140(11):1206-1220doi: 10.5858/arpa.2016-0156-RA.
Aisner, D. L., Rumery, M. D., Merrick, D. T., Kondo, K. L., Nijmeh, H., Linderman, D. J., Doebele, R. C., Thomas, N., Chesnut, P. C., Varella-Garcia, M., Franklin, W. A., & Camidge, D. R. (2016). Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Archives of pathology & laboratory medicine, 140(11), 1206-1220. https://doi.org/10.5858/arpa.2016-0156-RA
Aisner, Dara L, et al. "Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience." Archives of pathology & laboratory medicine vol. 140,11 (2016): 1206-1220. doi: https://doi.org/10.5858/arpa.2016-0156-RA
Aisner DL, Rumery MD, Merrick DT, Kondo KL, Nijmeh H, Linderman DJ, Doebele RC, Thomas N, Chesnut PC, Varella-Garcia M, Franklin WA, Camidge DR. Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med. 2016 Nov;140(11):1206-1220. doi: 10.5858/arpa.2016-0156-RA. Epub 2016 Sep 09. PMID: 27610643; PMCID: PMC5509499.
Copy Download .nbib Format: NLM
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.

Clinical lung cancer

Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC.
PMID: 34753703
Clin Lung Cancer. 2021 Oct 10; doi: 10.1016/j.cllc.2021.10.002. Epub 2021 Oct 10.

BACKGROUND: The phase III S0819 trial investigated addition of cetuximab to first-line chemotherapy (CT) in NSCLC. Subgroup analyses suggested an OS benefit among patients with EGFR copy number gain in squamous cell carcinomas (SCC), (HR = 0.58 [0.39-0.86], P...

Cite
Hirsch FR, Redman MW, Moon J, et al. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clin Lung Cancer. 2021;doi: 10.1016/j.cllc.2021.10.002.
Hirsch, F. R., Redman, M. W., Moon, J., Agustoni, F., Herbst, R. S., Semrad, T. J., Varella-Garcia, M., Rivard, C. J., Kelly, K., Gandara, D. R., & Mack, P. C. (2021). EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clinical lung cancer, . https://doi.org/10.1016/j.cllc.2021.10.002
Hirsch, Fred R, et al. "EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC." Clinical lung cancer vol. (2021). doi: https://doi.org/10.1016/j.cllc.2021.10.002
Hirsch FR, Redman MW, Moon J, Agustoni F, Herbst RS, Semrad TJ, Varella-Garcia M, Rivard CJ, Kelly K, Gandara DR, Mack PC. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. Clin Lung Cancer. 2021 Oct 10; doi: 10.1016/j.cllc.2021.10.002. Epub 2021 Oct 10. PMID: 34753703.
Copy Download .nbib Format: NLM
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models.

Frontiers in pharmacology

Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG.
PMID: 23543898
Front Pharmacol. 2013 Mar 28;4:35. doi: 10.3389/fphar.2013.00035. eCollection 2013.

The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC)...

Cite
Pitts TM, Kulikowski GN, Tan AC, et al. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013;4:35doi: 10.3389/fphar.2013.00035.
Pitts, T. M., Kulikowski, G. N., Tan, A. C., Murray, B. W., Arcaroli, J. J., Tentler, J. J., Spreafico, A., Selby, H. M., Kachaeva, M. I., McPhillips, K. L., Britt, B. C., Bradshaw-Pierce, E. L., Messersmith, W. A., Varella-Garcia, M., & Eckhardt, S. G. (2013). Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in pharmacology, 435. https://doi.org/10.3389/fphar.2013.00035
Pitts, Todd M, et al. "Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models." Frontiers in pharmacology vol. 4 (2013): 35. doi: https://doi.org/10.3389/fphar.2013.00035
Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013 Mar 28;4:35. doi: 10.3389/fphar.2013.00035. eCollection 2013. PMID: 23543898; PMCID: PMC3610060.
Copy Download .nbib Format: NLM
Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir.

Nanomaterials (Basel, Switzerland)

Di Donato C, Iacovino R, Isernia C, Malgieri G, Varela-Garcia A, Concheiro A, Alvarez-Lorenzo C.
PMID: 32230723
Nanomaterials (Basel). 2020 Mar 27;10(4). doi: 10.3390/nano10040613.

Acyclovir (ACV) is one of the most used antiviral drugs for the treatment of herpes simplex virus infections and other relevant mucosal infections caused by viruses. Nevertheless, the low water solubility of ACV limits both its bioavailability and antiviral...

Cite
Di Donato C, Iacovino R, Isernia C, et al. Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir. Nanomaterials (Basel). 2020;10(4)doi: 10.3390/nano10040613.
Di Donato, C., Iacovino, R., Isernia, C., Malgieri, G., Varela-Garcia, A., Concheiro, A., & Alvarez-Lorenzo, C. (2020). Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir. Nanomaterials (Basel, Switzerland), 10(4), . https://doi.org/10.3390/nano10040613
Di Donato, Cristina, et al. "Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir." Nanomaterials (Basel, Switzerland) vol. 10,4 (2020). doi: https://doi.org/10.3390/nano10040613
Di Donato C, Iacovino R, Isernia C, Malgieri G, Varela-Garcia A, Concheiro A, Alvarez-Lorenzo C. Polypseudorotaxanes of Pluronic® F127 with Combinations of α- and β-Cyclodextrins for Topical Formulation of Acyclovir. Nanomaterials (Basel). 2020 Mar 27;10(4). doi: 10.3390/nano10040613. PMID: 32230723; PMCID: PMC7221812.
Copy Download .nbib Format: NLM
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Targeted oncology

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A.
PMID: 27056749
Target Oncol. 2016 Jun;11(3):429. doi: 10.1007/s11523-016-0433-x.

No abstract available.

Cite
Despierre E, Vergote I, Anderson R, et al. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2016;11(3):429doi: 10.1007/s11523-016-0433-x.
Despierre, E., Vergote, I., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Green, J. A., Steer, C., Berns, E. M., Casado, A., Lambrechts, D., & Jimeno, A. (2016). Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Targeted oncology, 11(3), 429. https://doi.org/10.1007/s11523-016-0433-x
Despierre, Evelyn, et al. "Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy." Targeted oncology vol. 11,3 (2016): 429. doi: https://doi.org/10.1007/s11523-016-0433-x
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A. Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. Target Oncol. 2016 Jun;11(3):429. doi: 10.1007/s11523-016-0433-x. PMID: 27056749.
Copy Download .nbib Format: NLM
Biologic and genetics aspects of chagas disease at endemic areas.

Journal of tropical medicine

Bellini MF, Silistino-Souza R, Varella-Garcia M, de Azeredo-Oliveira MT, Silva AE.
PMID: 22529863
J Trop Med. 2012;2012:357948. doi: 10.1155/2012/357948. Epub 2012 Mar 08.

The etiologic agent of Chagas Disease is the Trypanosoma cruzi, transmitted through blood-sucking insect vectors of the Triatominae subfamily, representing one of the most serious public health concerns in Latin America. There are geographic variations in the prevalence of...

Cite
Bellini MF, Silistino-Souza R, Varella-Garcia M, et al. Biologic and genetics aspects of chagas disease at endemic areas. J Trop Med. 2012;2012:357948doi: 10.1155/2012/357948.
Bellini, M. F., Silistino-Souza, R., Varella-Garcia, M., de Azeredo-Oliveira, M. T., & Silva, A. E. (2012). Biologic and genetics aspects of chagas disease at endemic areas. Journal of tropical medicine, 2012357948. https://doi.org/10.1155/2012/357948
Bellini, Marilanda Ferreira, et al. "Biologic and genetics aspects of chagas disease at endemic areas." Journal of tropical medicine vol. 2012 (2012): 357948. doi: https://doi.org/10.1155/2012/357948
Bellini MF, Silistino-Souza R, Varella-Garcia M, de Azeredo-Oliveira MT, Silva AE. Biologic and genetics aspects of chagas disease at endemic areas. J Trop Med. 2012;2012:357948. doi: 10.1155/2012/357948. Epub 2012 Mar 08. PMID: 22529863; PMCID: PMC3317048.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries